ArticleScientific reports2026
Chasteberry extract alleviates rotenone-triggered testicular injury in rats by modulating oxidative stress, inflammation, apoptosis, and mitochondrial dysfunction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widespread usage of the pesticide rotenone has been linked to several health issues in both people and animals. Thus, we aimed to counteract rotenone-induced testicular oxidative damage using Chasteberry extract (CBE), while concurrently investigating the underlying mechanisms. Forty male albino rats were randomized into four groups (10 rats per each group): served as control (received 1 mL of saline orally, and 2% dimethyl sulfoxide (DMSO) at a dose of 10 mL/kg for 3 times/week, intraperitoneally), CBE (165 mg/kg/daily, orally), rotenone (3 mg/kg/3times/week, intraperitonially), and combination (CBE and rotenone). Treatments were administered for 60 consecutive days. Our data indicated that rotenone injection resulted in hormonal imbalance, oxidative damage, inflammation, apoptosis, as well as mitochondrial dynamic dysfunction in testicular tissue. While the co-administration of CBE with rotenone significantly mitigated these deleterious effects and restored sperm morphology and count, as evidenced biochemically by upregulation in follicle-stimulating hormone, luteinizing hormone and testosterone hormonal levels. Also, the CBE-supplemented rotenone group showed enhanced antioxidant enzyme activities (superoxide dismutase, catalase, total and reduced glutathione) and reduced malondialdehyde levels, oxidized glutathione, and proinflammatory cytokine levels (tumor necrosis factor and interleukin 1β). These results were further confirmed by histopathological investigation, which revealed marked restoration of testicular histoarchitecture with reduction in nuclear factor kappa B and caspase 3 immunoreactivity in the combination group. On the molecular level, CBE supplementation restored the antioxidant mRNA transcript of antioxidant genes, mitochondrial biogenesis genes, and mitochondrial dynamics, as evidenced by upregulation in mitofusin and downregulation in dynamin-related protein 1. In conclusion, CBE is a promising protective agent against rotenone-induced testicular damage via its antioxidant, anti-inflammatory, antiapoptotic, and mitochondrial biogenesis-enhancing effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.